Department of Ophthalmology, The Permanente Medical Group, Roseville, CA, USA.
Department of Ophthalmology, The Permanent Medical Group, Vallejo, CA, USA.
Surv Ophthalmol. 2023 Jul-Aug;68(4):821-829. doi: 10.1016/j.survophthal.2022.09.003. Epub 2022 Sep 21.
A 43-year-old woman presented with decreased vision in the right eye associated with painful eye movements 10 days after receiving her first dose of Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine (Pfizer Inc, New York, NY). Two days later she developed painful loss of vision in the left eye. Clinical presentation and magnetic resonance imaging findings were consistent with bilateral optic perineuritis transitioning to optic neuritis. Extensive evaluation including aquaporin-4 immunoglobin G (IgG), myelin oligodendrocyte glycoprotein IgG, and lumbar puncture was unrevealing. Visual acuity at nadir was counting fingers in both eyes, but after receiving intravenous steroids and plasma exchange vision eventually improved to 20/20 in each eye, although she was left with inferior visual field defects and bilateral optic disc pallor. This case highlights the diagnostic challenge in the evaluation of atypical optic neuritis with a review of post-COVID-19 vaccination-associated optic neuritis.
一位 43 岁女性在接种辉瑞-生物科技公司的首剂 2019 冠状病毒病(COVID-19)疫苗(辉瑞公司,纽约州,纽约)10 天后出现右眼视力下降,并伴有眼球运动疼痛。两天后,她左眼出现疼痛性视力丧失。临床表现和磁共振成像结果符合双侧视神经鞘炎向视神经炎转变。广泛的评估包括水通道蛋白 4 免疫球蛋白 G(IgG)、髓鞘少突胶质细胞糖蛋白 IgG 和腰椎穿刺均未发现异常。双眼视力最低时仅能指数计数,但在接受静脉注射类固醇和血浆置换后,视力最终改善到双眼 20/20,尽管她仍存在下方视野缺损和双侧视盘苍白。本病例强调了在 COVID-19 疫苗接种后相关视神经炎评估中,对不典型视神经炎的诊断挑战,并对其进行了回顾。